Pre-eclampsia

被引:668
作者
Chappell, Lucy C. [1 ]
Cluver, Catherine A. [2 ,3 ]
Kingdom, John [4 ]
Tong, Stephen [5 ,6 ]
机构
[1] Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth, London SE1 7EH, England
[2] Stellenbosch Univ, Dept Obstet & Gynaecol, Stellenbosch, South Africa
[3] Tygerberg Hosp, Cape Town, South Africa
[4] Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada
[5] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia
[6] Mercy Hosp Women, Heidelberg, Vic, Australia
关键词
MATERNAL VASCULAR MALPERFUSION; PLACENTAL GROWTH-FACTOR; LOW-DOSE ASPIRIN; HYPERTENSIVE DISORDERS; DOUBLE-BLIND; PREVENTING PREECLAMPSIA; CARDIOVASCULAR-DISEASE; PREGNANT-WOMEN; HIGH-RISK; SUBSEQUENT PREGNANCY;
D O I
10.1016/S0140-6736(20)32335-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pre-eclampsia is a multisystem pregnancy disorder characterised by variable degrees of placental malperfusion, with release of soluble factors into the circulation. These factors cause maternal vascular endothelial injury, which leads to hypertension and multi-organ injury. The placental disease can cause fetal growth restriction and stillbirth. Pre-eclampsia is a major cause of maternal and perinatal mortality and morbidity, especially in low-income and middle-income countries. Prophylactic low-dose aspirin can reduce the risk of preterm pre-eclampsia, but once pre-eclampsia has been diagnosed there are no curative treatments except for delivery, and no drugs have been shown to influence disease progression. Timing of delivery is planned to optimise fetal and maternal outcomes. Clinical trials have reported diagnostic and prognostic strategies that could improve fetal and maternal outcomes and have evaluated the optimal timing of birth in women with late preterm pre-eclampsia. Ongoing studies are evaluating the efficacy, dose, and timing of aspirin and calcium to prevent pre-eclampsia and are evaluating other drugs to control hypertension or ameliorate disease progression.
引用
收藏
页码:341 / 354
页数:14
相关论文
共 134 条
[1]   Antihypertensive drug therapy for mild to moderate hypertension during pregnancy [J].
Abalos, Edgardo ;
Duley, Lelia ;
Steyn, D. Wilhelm ;
Gialdini, Celina .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (10)
[2]   Global and regional estimates of preeclampsia and eclampsia: a systematic review [J].
Abalos, Edgardo ;
Cuesta, Cristina ;
Grosso, Ana L. ;
Chou, Doris ;
Say, Lale .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2013, 170 (01) :1-7
[3]   Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers [J].
Akolekar, Ranjit ;
Syngelaki, Argyro ;
Poon, Leona ;
Wright, David ;
Nicolaides, Kypros H. .
FETAL DIAGNOSIS AND THERAPY, 2013, 33 (01) :8-15
[4]   Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis [J].
Alqudah, A. ;
McKinley, M. C. ;
McNally, R. ;
Graham, U. ;
Watson, C. J. ;
Lyons, T. J. ;
McClements, L. .
DIABETIC MEDICINE, 2018, 35 (02) :160-172
[5]   Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis [J].
Ananth, Cande V. ;
Keyes, Katherine M. ;
Wapner, Ronald J. .
BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
[6]   Gestational Hypertension and Preeclampsia [J].
Espinoza, Jimmy ;
Vidaeff, Alex ;
Pettker, Christian M. ;
Simhan, Hyagriv .
OBSTETRICS AND GYNECOLOGY, 2020, 135 (06) :E237-E260
[7]  
[Anonymous], 2018, Obstet Gynecol, V132, P254, DOI 10.1097/AOG.0000000000002709
[8]  
[Anonymous], 2016, PLOS ONE, DOI DOI 10.1371/journal.pone.0160562
[9]   Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data [J].
Askie, Lisa M. ;
Duley, Lelia ;
Henderson-Smart, David J. ;
Stewart, Lesley A. .
LANCET, 2007, 369 (9575) :1791-1798
[10]   Chronotherapy With Low-Dose Aspirin for Prevention of Complications in Pregnancy [J].
Ayala, Diana E. ;
Ucieda, Rafael ;
Hermida, Ramon C. .
CHRONOBIOLOGY INTERNATIONAL, 2013, 30 (1-2) :260-279